Pyrimidines

On February 9, 2021, Nagpal, Anushka; Dhankhar, Dinesh; Cesario, Thomas C.; Li, Runze; Chen, Jie; Rentzepis, Peter M. published an article.Recommanded Product: 65-71-4 The title of the article was Thymine dissociation and dimer formation: A Raman and synchronous fluorescence spectroscopic study. And the article contained the following:

In this study, absorption, fluorescence, synchronous fluorescence, and Raman spectra of nonirradiated and UV-irradiated thymine solutions were recorded in order to detect thymine dimer formation. The thymine dimer formation, as a function of irradiation dose, was determined by Raman spectroscopy. In addition, the formation of a mutagenic (6-4) photoproduct was identified by its synchronous fluorescence spectrum. Our spectroscopic data suggest that the rate of conversion of thymine to thymine dimer decreases after 20 min of UV irradiation, owing to the formation of an equilibrium between the thymine dimers and monomers. However, the formation of the (6-4) photoproduct continued to increase with UV irradiation In addition, the Raman spectra of nonirradiated and irradiated calf thymus DNA were recorded, and the formation of thymine dimers was detected. The spectroscopic data presented make it possible to determine the mechanism of thymine dimer formation, which is known to be responsible for the inhibition of DNA replication that causes bacteria inactivation. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to raman synchronous fluorescence spectroscopy thymine dissociation dimer formation, dna, uv inactivation, spectroscopy, thymine dimer, thymine dimer raman spectrum, General Biochemistry: Nucleic Acids and Their Constituents and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 5, 2018, Kozanecka-Okupnik, Weronika; Jasiewicz, Beata; Pospieszny, Tomasz; Jastrzab, Renata; Skrobanska, Monika; Mrowczynska, Lucyna published an article.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Spectroscopy, molecular modeling and anti-oxidant activity studies on novel conjugates containing indole and uracil moiety. And the article contained the following:

Herein we describe our results on the synthesis and mol. modeling of new conjugates containing indole and uracil moiety. This group of compounds was synthesized by the reaction of indole alkaloid – gramine with appropriate uracil (uracil, 2-thiouracil, 6-methyl-2-thiouracil, thymine, 6-methyluracil and barbituric acid) using DMF as solvent. The structures of all products were confirmed by spectroscopic (1H NMR, 13C NMR, and FT-IR) anal., mass spectrometry (EI) and PM5 semiempirical methods. Moreover the protonation constants for studied compounds were determined The obtained conjugates were screened in vitro for antioxidant and haemolytic activities, and for the protective effects against 2,2′-azobis (2-methylpropionamidine) dihydrochloride (AAPH)-induced oxidative haemolysis of human erythrocytes. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to oxidant conjugate indole alkaloid uracil preparation, Alkaloids: Alkaloids Containing One Nitrogen Atom In A Ring and other aspects.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 14, 2013, Nagase, Hiroshi; Fujii, Hideaki; Nakata, Eriko; Watanabe, Yoshikazu; Takahashi, Toshihiro published a patent.HPLC of Formula: 596114-50-0 The title of the patent was Preparation of morphinan derivatives as opioid δ receptor agonists. And the patent contained the following:

Title compounds I [R1 = H, alkyl, aryl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3-R5 = independently H, hydroxy, halo, etc.; R6a, R6b = independently H, F or hydroxy; R6a and R6b may combine to form oxo; R7, R8 = independently H, F or hydroxy; R9, R10 = independently H, alkyl, aryl, etc.; X = O or CH2; Y = C:O, C:S, SO2, etc.; or pharmacol. acceptable salts thereof] were prepared For example, reaction of (1S,3aS,5aS,6R,11bR,11cR)-3-benzyl-14-(cyclopropylmethyl)-3a,11-dihydroxy-10-methoxy-1,3,3a,4,5,6,7,11c-octahydro-2H-6,11b-(iminoethano)-1,5a-expoxynaphtho[1,2-e]indol-2-one with BH3·THF, treatment with PhBr/K2CO3/Cu, exposure to ethylenediamine/sodium silica-gel (stage I), debenzylation, benzoylation, and demethylation using BBr3 afforded compound II. In opioid receptor agonist activity test, the selected invention compounds, e.g., II, showed EC50 of <1 nM for opioid δ receptor. Compounds I are claimed useful for the treatment of pain. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).HPLC of Formula: 596114-50-0

The Article related to morphinan preparation opioid delta receptor agonist, analgesic morphinan opioid delta receptor agonist, Alkaloids: Alkaloids Containing One Nitrogen Atom In A Ring and other aspects.HPLC of Formula: 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hao, Yiming; Yuan, Xue; Qian, Peng; Bai, Guanfeng; Wang, Yiqin published an article in 2017, the title of the article was The serum analysis of dampness syndrome in patients with coronary heart disease and chronic renal failure based on the theory of “same syndromes in different diseases”.Application In Synthesis of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione And the article contains the following content:

Aim. To analyze the serum metabolites in patients with coronary heart disease (CHD) showing dampness syndrome and patients with chronic renal failure (CRF) showing dampness syndrome and to seek the substance that serves as the underlying basis of dampness syndrome in “same syndromes in different diseases.” Methods. Metabolic spectrum by GC-MS was performed using serum samples from 29 patients with CHD showing dampness syndrome and 32 patients with CRF showing dampness syndrome. The principal component anal. and statistical anal. of partial least squares were performed to detect the metabolites with different levels of expression in patientswith CHDand CRF. Furthermore, by comparing the VIP value and data mining inMETLIN and HMDB, we identified the common metabolites in both patient groups. Results. (1) Ten differential metabolites were found in patients with CHD showing dampness syndrome when compared to healthy subjects. Meanwhile, nine differential metabolites were found in patients with CRF showing dampness syndrome when compared to healthy subjects. (2) There were 9 differential metabolites identified when the serum metabolites of the CHD patients with dampness syndrome were compared to those of CRF patients with dampness syndrome.There were 4 common metabolites found in the serums of both patient groups. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Application In Synthesis of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to human chd renal failure serum analysis dampness syndrome, Mammalian Pathological Biochemistry: Cardiovascular Diseases and other aspects.Application In Synthesis of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

D’Antonio, Matteo; Nguyen, Jennifer P.; Arthur, Timothy D.; Matsui, Hiroko; Donovan, Margaret K. R.; D’Antonio-Chronowska, Agnieszka; Frazer, Kelly A. published an article in 2022, the title of the article was In heart failure reactivation of RNA-binding proteins is associated with the expression of 1,523 fetal-specific isoforms.COA of Formula: C5H6N2O2 And the article contains the following content:

Reactivation of fetal-specific genes and isoforms occurs during heart failure. However, the underlying mol. mechanisms and the extent to which the fetal program switch occurs remains unclear. Limitations hindering transcriptome-wide analyses of alternative splicing differences (i.e. isoform switching) in cardiovascular system (CVS) tissues between fetal, healthy adult and heart failure have included both cellular heterogeneity across bulk RNA-seq samples and limited availability of fetal tissue for research. To overcome these limitations, we have deconvoluted the cellular compositions of 996 RNA-seq samples representing heart failure, healthy adult (heart and arteria), and fetal-like (iPSC-derived cardiovascular progenitor cells) CVS tissues. Comparison of the expression profiles revealed that reactivation of fetal-specific RNA-binding proteins (RBPs), and the accompanied re-expression of 1,523 fetal-specific isoforms, contribute to the transcriptome differences between heart failure and healthy adult heart. Of note, isoforms for 20 different RBPs were among those that reverted in heart failure to the fetal-like expression pattern. We determined that, compared with adult-specific isoforms, fetal-specific isoforms encode proteins that tend to have more functions, are more likely to harbor RBP binding sites, have canonical sequences at their splice sites, and contain typical upstream polypyrimidine tracts. Our study suggests that compared with healthy adult, fetal cardiac tissue requires stricter transcriptional regulation, and that during heart failure reversion to this stricter transcriptional regulation occurs. Furthermore, we provide a resource of cardiac developmental stage-specific and heart failure-associated genes and isoforms, which are largely unexplored and can be exploited to investigate novel therapeutics for heart failure. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).COA of Formula: C5H6N2O2

The Article related to transcriptome mbnl1 fmr1 matr3 ipsc exoc7 heart failure adult, Mammalian Pathological Biochemistry: Cardiovascular Diseases and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 30, 2022, Bonifacio, Lillian Gonzalez; Melo, Mirele; Ayo, Christiane Maria; Assoni, Leticia Carolina Paraboli; Olimpio, Larissa Martins; Nogueira, Mariana Reis; Spegiorin, Ligia Cosentino Junqueira Franco; Barbosa, Deusenia Machado Ulisses; de Mattos, Luiz Carlos; Pereira-Chioccola, Vera Lucia; Brandao, Cinara Cassia published an article.Formula: C5H6N2O2 The title of the article was TNFalpha rs1799964 TT genotype may be a susceptibility factor for vertical transmission of Toxoplasma gondii and clinical signs in newborns from pregnant women with acute toxoplasmosis. And the article contained the following:

One of the main impacts of Toxoplasma gondii infection occurs during pregnancy and is related to the vertical transmission of the parasite (congenital toxoplasmosis), which can cause severe clin. outcomes and fetal death. During acute infection, in order to control the rapid replication of tachyzoites, different host immune response genes are activated, and these include cytokine-encoding genes. Considering that polymorphisms in cytokine genes may increase susceptibility to vertical transmission of T. gondii by determining the immune status of the pregnant woman, this study evaluated the influence of polymorphisms of tumor necrosis factor alpha (TNFα) rs1799964 (- 1031) and interleukin 1 beta (IL1β) rs16944 (- 511) genes on gestational toxoplasmosis and on the vertical transmission of the parasite and verified the allele and genotype frequency of these polymorphisms in pregnant patients whose resp. newborn did or did not present clin. abnormalities suggestive of congenital toxoplasmosis. Methods and results: A total of 204 pregnant patients with (n = 114) or without (n = 90) infection by T. gondii were enrolled. No associations were found involving the polymorphisms rs1799964 (- 1031) of the TNFα gene and rs16944 (- 511) of the IL1β gene with the increased chance of T. gondii infection during pregnancy. However, it was observed that the maternal TT genotype referring to the polymorphism of the TNFα gene seems to influence the vertical transmission of the parasite (P = 0.01; χ2 = 6.05) and the presence of clin. manifestation in newborns from pregnancies with acute toxoplasmosis (P = 0.007; χ2 = 9.68). Conclusion: The TNFα rs1799964 TT genotype may act as a susceptibility factor for the vertical transmission of parasite and for the presence of clin. signs in newborns from pregnant women with acute toxoplasmosis. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Formula: C5H6N2O2

The Article related to toxoplasma tnfalpha genotype acute toxoplasmosis pregnancy newborn, gestational toxoplasmosis, polymorphisms, tnfα and il1β, toxoplasmosis, Mammalian Pathological Biochemistry: Obstetrics – Gynecology and other aspects.Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 16, 2015, Liang, Ruiyong; Gao, Hai published a patent.Category: pyrimidines The title of the patent was Waterborne sloughing-resistant coating. And the patent contained the following:

The title coating is composed of (by weight parts): ethylene-acrylic acid copolymer 100-120, ammonium aluminum sulfate 1-2, sodium borohydride 0.5-1, epoxidized triglyceride 2-3, expanded perlite 3-5, hydroxypropyl methylcellulose 1-2, tristearin 2-3, 2-mercaptobenzimidazole 0.6-2, mannitol 1-2, talc powder 10-13, bis-imidazolidinyl urea 0.5-1, silicon carbide micropowder 4-6, flame retardant aid 2-4, and deionized water 25-30. The flame retardant aid is composed of: microcapsulated red phosphorus, polycarbonate, aluminum magnesium silicate, lithium-based bentonite, trimethoprim lactate, trimethylolpropane, and isooctyl acrylate. The coating can be used for spray coating of metal material, and is adapted to aerial spraying. The coating film formed from the coating has high surface resistance, high impact strength, and good protective effect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to aqueous coating, Coatings, Inks, and Related Products: Other Coating Materials and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 22, 2015, Zhou, Chang; Li, Shouguo published a patent.Related Products of 23256-42-0 The title of the patent was Waterborne antirust paint having coating process without rust surface pretreatment. And the patent contained the following:

The present invention discloses waterborne antirust paint having coating process without rust surface pretreatment. The paint is composed of (by parts) isophorone oxide 0.3-1, alkyd resin 10-13, tea saponin 1-2, 2-mercaptobenzimidazole 1-2, slag powder 0.3-0.5, Capsicum frutescens powder 0.7-1, polyhexamethylene guanidine 0.8-2, barium metaborate 3-4, bauxite 4-6, polyacrylamide 0.7-1, potassium dihydrogen phosphate 1-2, isooctyl methacrylate 4-5, waterborne acrylic emulsion 100-110 sodium hexametaphosphate 0.5-1, additives 2-3, dimethicone 0.1-0.2 and deionized water 6-10. The additive is composed of chlorinated polyether resin, calcium aluminate powder, zinc borate, propylene glycol Bu ether, trimethoprim lactate, sodium myristate soap, hydroxyethyl cellulose and deionized water. The antirust paint of the present invention has excellent corrosion resistance and no environmental pollution (by using water as solvent), and can be applied directly to surface without rust pretreatment by spray coating or brush coating. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to waterborne antirust coating, Coatings, Inks, and Related Products: Other Coating Materials and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 15, 2017, Nguyen, Kim; Fazio, Michael; Kubota, Miles; Nainar, Sarah; Feng, Chao; Li, Xiang; Atwood, Scott X.; Bredy, Timothy W.; Spitale, Robert C. published an article.Formula: C5H6N2O3 The title of the article was Cell-Selective Bioorthogonal Metabolic Labeling of RNA. And the article contained the following:

Stringent chem. methods to profile RNA expression within discrete cellular populations remains a key challenge in biol. To address this issue, the authors developed a chem.-genetic strategy for metabolic labeling of RNA. Cell-specific labeling of RNA can be profiled and imaged using bioorthogonal chem. The authors anticipate that this platform will provide the community with a much-needed chem. toolset for cell-type specific profiling of cell-specific transcriptomes derived from complex biol. systems. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Formula: C5H6N2O3

The Article related to cell bioorthogonal labeling rna, Biochemical Methods: Other (Not Covered At Other Subsections) and other aspects.Formula: C5H6N2O3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 14, 2015, Xia, Mingcai published a patent.COA of Formula: C17H24N4O6 The title of the patent was Hydrophobic wear-resistant coatings and their preparation method. And the patent contained the following:

The coatings contain trimethoprim lactate salt 0.6-1, polyethylene benzenesulfonic acid (sic) 0.5-1, allyl alc. 2-3, anhydrous CaCl2 1-2, polyacrylamide 2-3, MgCl2 2-4, phthalate 3-4, potassium dihydrogen phosphate 1-2, 2-thiobenzimidazole 1-2, triammonium molybdate 1-2, dry carbide slags 4-6, bentonite 10-13, hexamethylcyclotrisiloxane 80-100, Bu methacrylate 60-100, Et methacrylate 50-60, hexyl acrylate 130-200, deionized water 500-600, potassium persulfate 2-4, OP-10 3-4, and binders 3-6 parts. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).COA of Formula: C17H24N4O6

The Article related to hydrophobic wear resistant coating, Coatings, Inks, and Related Products: Other Coating Materials and other aspects.COA of Formula: C17H24N4O6

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia